ZLZi-Hui Li

Zi-Hui Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zi-Hui Li has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Dong Zhao

    Department of Rehabilitation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    1 shared publication
  • Feixiang Wu

    Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China

    1 shared publication
  • Jia-Zhou Ye

    Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, He Di Rd #71, Nanning, 530021, People's Republic of China

    1 shared publication
  • Jie Chen

    Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China

    1 shared publication
  • Kailiang Xu

    Department of Urology, Jingzhou Central Hospital, Jingzhou Hospital Affiliated to Yangtze University

    1 shared publication
  • Le-Qun Li

    Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People's Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Identification of key genes potentially associated with bladder cancer development by common plasticizers: an integrated transcriptomics and network toxicology study

    by Qiuqiu Zhang, Kailiang Xu, Zhongjun Chen, Zihui Li, Dong Zhao

    Purpose: Bladder cancer (BCa) is a prevalent urological malignancy. The relationship between plasticizers and BCa remains to be elucidated. The present study aimed to investigate the potential relationship between BCa and plasticizers. Methods: BCa-related data were obtained from public databases. We performed simultaneous prediction of plasticizer toxicity, as well as identification of plasticizer−related genes (PRGs) and BCa−related target genes (BCRTGs). Key genes were then identified via machine learning and the expression of the screened genes was detected using qRT-PCR. We explored the effects of key genes in BCa tumorigenesis by gene set enrichment analysis (GSEA) and constructing a molecular regulatory network using Cytoscape software. Molecular docking and molecular dynamics (MD) simulation were employed to assess the binding affinity between plasticizers and key genes. Finally, the immune microenvironment of BCa was explored. Principal results: The comprehensive data set contains a total of 4,642 differentially expressed genes. In addition, 225 PRGs and 196 BCRTGs were obtained from various online databases, and then seven candidate genes were obtained. Functional analyses revealed key potential mechanisms in BCa, such as the cell differentiation-related pathways and PI3K-Akt signaling pathway. Furthermore, five key genes (CCNE1, KIT, BCL2, TGFBR2, FASN) were then identified. In comparison to normal cells, FASN and CCNE1 exhibited elevated expression levels, while KIT, BCL2, and TGFBR2 demonstrated reduced expression in BCa cells. GSEA revealed that a subset of genes were co-enriched in cell cycle regulation. Molecular regulatory network showed that key genes have shared microRNAs (miRNAs) and TFs between them. Molecular docking and MD simulations demonstrated favorable binding affinities between the proteins encoded by the five key genes and the 3 plasticizers. Further findings revealed dysregulated infiltration levels of immune cells, including activated B cells, in BCa. Major conclusions: Five genes (CCNE1, KIT, BCL2, TGFBR2, FASN) were identified. This study used bioinformatics and network pharmacology to generate hypotheses about the possible molecular mechanisms underlying the association between plasticizer exposure and BCa, offering insights for new therapeutic approaches.

  • Open Access

    The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

    by Fei-Xiang Wu, Jie Chen, Tao Bai, Shao-Liang Zhu, Tian-Bo Yang, Lu-Nan Qi, Ling Zou, Zi-Hui Li, Jia-Zhou Ye, Le-Qun Li

    Sorafenib and transarterial chemoembolization (TACE) are recommended therapies for advanced hepatocellular carcinoma (HCC), but their combined efficacy remains unclear. Between August 2004 and November 2014, 104 patients with BCLC stage B/C HCC were enrolled at the Affiliated Tumor Hospital of Guangxi Medical University, China. Forty-eight patients were treated with sorafenib alone (sorafenib group) and 56 with TACE plus sorafenib (TACE + sorafenib group). Baseline demographic/clinical data were collected. The primary outcomes were median overall survival (OS) and progression-free survival (PFS). Secondary outcomes were overall response rate (ORR) and sorafenib-related adverse events (AEs). Baseline characteristics associated with disease prognosis were identified using multivariate Cox hazards regression. The mean age of the 104 patients (94 males; 90.38%) was 49.02 ± 12.29 years. Of the baseline data, only albumin level (P = 0.028) and Child-Pugh class (P = 0.017) differed significantly between groups. Median OS did not differ significantly between the sorafenib and TACE + sorafenib groups (18.0 vs. 22.0 months, P = 0.223). Median PFS was significantly shorter in the sorafenib group than that in the TACE + sorafenib group (6.0 vs. 8.0 months, P = 0.004). Six months after treatments, the ORRs were similar between the sorafenib and TACE + sorafenib groups (12.50% vs. 18.75%, P = 0.425). The rates of grade III–IV adverse events in sorafenib and TACE + sorafenib groups were 29.2% vs. 23.2%, respectively. TACE plus sorafenib treatment (HR = 0.498, 95% CI = 0.278–0.892), no vascular invasion (HR = 0.354, 95% CI = 0.183–0.685) and Child-Pugh class A (HR = 0.308, 95% CI = 0.141–0.674) were significantly associated with better OS, while a larger tumor number was predictive of poorer OS (HR = 1.286, 95% CI = 1.031–1.604). TACE plus sorafenib treatment (HR = 0.461, 95% CI = 0.273–0.780) and no vascular invasion (HR = 0.557, 95% CI = 0.314–0.988) were significantly associated with better PFS. Compared with sorafenib alone, combining TACE with sorafenib might prolong survival and delay disease progression in patients with advanced HCC.